Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE Cancer study.

CONCLUSIONS: The rates of recurrent VTE or major bleeding are relatively low among patients with active cancer receiving extended anticoagulant therapy beyond 6 months. Extended treatment with oral edoxaban appears as effective and safe as subcutaneous dalteparin. This article is protected by copyright. All rights reserved. PMID: 31271705 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31271705?dopt=Abstract

Source: Thrombosis and Haemostasis - July 3, 2019 Category: Hematology Authors: Di Nisio M, van Es N, Carrier M, Wang TF, Garcia D, Segers A, Weitz J, Buller H, Raskob G Tags: J Thromb Haemost Source Type: research